Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Prevacid® brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2021
Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin,Avelumab,Lansoprazole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : University of Manchester
Deal Size : Inapplicable
Deal Type : Inapplicable
Aspirin to Be Trialled as Part of New Treatment for Aggressive Form of Breast Cancer
Details : Breast Cancer Now said successful results could lead to further clinical trials of aspirin and avelumab for incurable secondary triple negative breast cancer, which happens when cancer cells that started in the breast spread to other parts of the body.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2021
Lead Product(s) : Aspirin,Avelumab,Lansoprazole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : University of Manchester
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
